STUDY NUMBER: 2600357

Dear pioneer,

A study to the **treatment of allergic lung diseases** will soon start at our research centre in Edegem.
Are you interested in participating and giving science a boost?
Hereby we would like to give you an overview of the study: duration of **± 54 weeks**.

In this cohort, the study medication will be administered **intravenously (IV).**

Additional procedure at UZA

You must be willing to undergo an additional examination at UZA:

BAL (bronchoscopy with bronchoalveolar lavage): a procedure performed under sedation during which a pulmonologist examines the airways using a small camera. A small amount of saline solution is introduced into the lungs and then collected again for further laboratory analysis.

Important information: Please do not wear nail polish, gel polish, or artificial/gel nails on the day of the screening visit, as your oxygen saturation will be measured.

INCLUSION CRITERIA

- **Last participation in other clinical study (final study):**
  SAD Cohort 2 sentinel: no later than **30 October 2026 (12 weeks before dosing)**
  **Be careful: Final study visit of the previous study needs to be performed to be able to participate at screening.*

- Healthy males and non-childbearing potential females aged 18 to 65 years (inclusive)
- BMI: between 18,5 and 30.5 kg/m²
- Minimum body weight of 50.0 kg (inclusive)
- Weight between 50.0 and 120.0 kg (inclusive)
- Non-smoker or stopped smoking at least 3 months before screening
- Use of nicotine-containing products (e.g. nicotine patches) must have been stopped at least 3 months before screening
- No use of medication during the 2 weeks prior to first dosing (exceptions only after consultation with the study physician)

- Contraception:
  - **Non-childbearing potential females**
    - Postmenopausal* (no menstruation for at least 12 months)
    - **OR** undergone a hysterectomy (removal of the uterus)
    - **OR** undergone bilateral oophorectomy (removal of both ovaries)
    - **OR** undergone bilateral salpingectomy (removal of both fallopian tubes)
  - **Men**: From screening until the end of the study:
    - Use of a condom
    - During every sexual intercourse
    - OR vasectomy
    - OR abstinence from all sexual intercourse
    - AND no sperm donation
- No blood donation (>450 mL), significant blood loss, or blood transfusion within 12 weeks before first dosing

- You will be asked to comply with restrictions regarding physical activity and the consumption of caffeine-containing and alcoholic products
- You are not an employee or family member of the sponsor, argenx BV, and not an SGS employee directly involved in the study
    - **You are not eligible if you:**
        - Have a history of hepatitis B, hepatitis C, or HIV
        - Have a relevant medical or psychiatric condition

INTEREST IN PARTICIPATING

Registration for this study only indicates your interest and does not obligate you to participate, nor us to include you as a participant.

Thank you in advance for your interest and we hope to welcome you soon for study 2600357.

SGS CPU